Biblio
Export 1654 results:
Author [ Title] Type Year Filters: First Letter Of Last Name is C [Clear All Filters]
“Copy Number Variants in Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 1, pp. 37-52, 2017.
, “Copy Number Variants in Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 1, pp. 37-52, 2017.
, “Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease.”, J Alzheimers Dis, 2015.
, “The Correlation of Tau Levels with Blood Monocyte Count in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1321-1328, 2022.
, “Cortical Amyloid Burden Differences Across Empirically-Derived Mild Cognitive Impairment Subtypes and Interaction with APOE ɛ4 Genotype.”, J Alzheimers Dis, vol. 52, no. 3, pp. 849-61, 2016.
, “Cortical Thickness and Its Association with Clinical Cognitive and Neuroimaging Markers in Cerebral Amyloid Angiopathy.”, J Alzheimers Dis, vol. 81, no. 4, pp. 1663-1671, 2021.
, “Cortical Transcriptional Profiles in APOE4 Carriers with Alzheimer's Disease: Patterns of Protection and Degeneration.”, J Alzheimers Dis, 2015.
, “Cortical Transcriptional Profiles in APOE4 Carriers with Alzheimer's Disease: Patterns of Protection and Degeneration.”, J Alzheimers Dis, 2015.
, “A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer's Disease: Results from the MOPEAD Project.”, J Alzheimers Dis, vol. 83, no. 3, pp. 1149-1159, 2021.
, “Costs During the Last Five Years of Life for Patients with Clinical and Pathological Confirmed Diagnosis of Lewy Body Dementia and Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 457-466, 2023.
, “Could Altered Evoked Pain Responsiveness Be a Phenotypic Biomarker for Alzheimer's Disease Risk? A Cross-Sectional Analysis of Cognitively Healthy Individuals.”, J Alzheimers Dis, vol. 79, no. 3, pp. 1227-1233, 2021.
, “Could Altered Evoked Pain Responsiveness Be a Phenotypic Biomarker for Alzheimer's Disease Risk? A Cross-Sectional Analysis of Cognitively Healthy Individuals.”, J Alzheimers Dis, vol. 79, no. 3, pp. 1227-1233, 2021.
, “Course and Determinants of Anosognosia in Alzheimer's Disease: A 12-Month Follow-up.”, J Alzheimers Dis, vol. 51, no. 2, pp. 357-66, 2016.
, “Course and Determinants of Anosognosia in Alzheimer's Disease: A 12-Month Follow-up.”, J Alzheimers Dis, vol. 51, no. 2, pp. 357-66, 2016.
, “COVID-19: Association Between Increase of Behavioral and Psychological Symptoms of Dementia During Lockdown and Caregivers' Poor Mental Health.”, J Alzheimers Dis, vol. 80, no. 4, pp. 1713-1721, 2021.
, “COVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications.”, J Alzheimers Dis, vol. 77, no. 2, pp. 459-504, 2020.
, “COVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications.”, J Alzheimers Dis, vol. 77, no. 2, pp. 459-504, 2020.
, “A Critical Proton MR Spectroscopy Marker of Alzheimer's Disease Early Neurodegenerative Change: Low Hippocampal NAA/Cr Ratio Impacts APOE ɛ4 Mexico City Children and Their Parents.”, J Alzheimers Dis, 2015.
, “Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson's Disease1.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1261-1272, 2017.
, “Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson's Disease1.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1261-1272, 2017.
, “A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.”, J Alzheimers Dis, vol. 59, no. 2, pp. 603-614, 2017.
, “A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.”, J Alzheimers Dis, vol. 59, no. 2, pp. 603-614, 2017.
, “Curcumin Ameliorates Neuroinflammation, Neurodegeneration, and Memory Deficits in p25 Transgenic Mouse Model that Bears Hallmarks of Alzheimer's Disease.”, J Alzheimers Dis, vol. 60, no. 4, pp. 1429-1442, 2017.
, “Damage to the Frontal Aslant Tract Accounts for Visuo-Constructive Deficits in Alzheimer's Disease.”, J Alzheimers Dis, vol. 60, no. 3, pp. 1015-1024, 2017.
, “Damage to the Frontal Aslant Tract Accounts for Visuo-Constructive Deficits in Alzheimer's Disease.”, J Alzheimers Dis, vol. 60, no. 3, pp. 1015-1024, 2017.
,